Antihyperlipidemics HMGCo-A Reductase Inhibitors (Statins)

Antihyperlipidemics: HMG-CoA reductase inhibitors, commonly referred to as statins, are a foundational class of lipid-lowering therapeutic agents Clinically, these medications are primarily prescribed to treat primary hyperlipidemia and mixed dyslipidemia, as well as for the primary and secondary prevention of atherosclerotic cardiovascular disease, including myocardial infarction and ischemic stroke

Antihyperlipidemics: HMG-CoA reductase inhibitors, commonly referred to as statins, are a foundational class of lipid-lowering therapeutic agents They function by competitively inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A reductase, the rate-limiting enzyme in hepatic cholesterol biosynthesis, which triggers an upregulation of hepatic low-density lipoprotein (LDL) receptors and accelerates the clearance of circulating atherogenic lipoproteins

They function by competitively inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A reductase, the rate-limiting enzyme in hepatic cholesterol biosynthesis, which triggers an upregulation of hepatic low-density lipoprotein (LDL) receptors and accelerates the clearance of circulating atherogenic lipoproteins

Clinically, these medications are primarily prescribed to treat primary hyperlipidemia and mixed dyslipidemia, as well as for the primary and secondary prevention of atherosclerotic cardiovascular disease, including myocardial infarction and ischemic stroke

Clinically, these medications are primarily prescribed to treat primary hyperlipidemia and mixed dyslipidemia, as well as for the primary and secondary prevention of atherosclerotic cardiovascular disease, including myocardial infarction and ischemic stroke